

# Jeffrey M Trent

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7268419/publications.pdf>

Version: 2024-02-01

24  
papers

3,094  
citations

430874

18  
h-index

610901

24  
g-index

26  
all docs

26  
docs citations

26  
times ranked

4873  
citing authors

#	ARTICLE	IF	CITATIONS
1	A pilot study of genomicâ€‘guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for highâ€‘risk neuroblastoma. <i>Cancer Reports</i> , 2022, 5, e1616.	1.4	5
2	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. <i>PLoS ONE</i> , 2021, 16, e0248097.	2.5	5
3	The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series. <i>Oncotarget</i> , 2021, 12, 1836-1847.	1.8	1
4	Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing. <i>Nature Biotechnology</i> , 2021, 39, 1151-1160.	17.5	39
5	Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. <i>Cancer Research</i> , 2021, 81, 5818-5832.	0.9	10
6	HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases. <i>Cancer Research</i> , 2020, 80, 3009-3022.	0.9	19
7	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthaseâ€‘Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020, 26, 4402-4413.	7.0	21
8	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. <i>Clinical Cancer Research</i> , 2018, 24, 1932-1943.	7.0	51
9	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2767-2779.	4.1	50
10	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , 2018, 14, e1007589.	3.5	56
11	The histone methyltransferase <sc>EZH2</sc> is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2017, 242, 371-383.	4.5	78
12	Integrated genomic analyses reveal frequent <i>TERT</i> aberrations in acral melanoma. <i>Genome Research</i> , 2017, 27, 524-532.	5.5	122
13	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. <i>Gynecologic Oncology</i> , 2016, 141, 454-460.	1.4	85
14	Dual loss of the <sc>SWI</sc>/<sc>SNF</sc> complex <sc>ATPases SMARCA4</sc>/<sc>BRG1</sc> and <sc>SMARCA2</sc>/<sc>BRM</sc> is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2016, 238, 389-400.	4.5	169
15	Perspectives from manâ€™s best friend: National Academy of Medicineâ€™s Workshop on Comparative Oncology. <i>Science Translational Medicine</i> , 2016, 8, 324ps5.	12.4	108
16	Feasibility of implementing molecularâ€‘guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. <i>Cancer Medicine</i> , 2015, 4, 871-886.	2.8	26
17	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Nonâ€‘V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971.	4.1	25
18	Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). <i>Rare Diseases (Austin, Tex )</i> , 2014, 2, e967148.	1.8	40

#	ARTICLE	IF	CITATIONS
19	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. Clinical Cancer Research, 2014, 20, 4200-4209.	7.0	127
20	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nature Genetics, 2014, 46, 427-429.	21.4	298
21	Prospective Molecular Profiling of Canine Cancers Provides a Clinically Relevant Comparative Model for Evaluating Personalized Medicine (PMed) Trials. PLoS ONE, 2014, 9, e90028.	2.5	33
22	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nature Genetics, 2012, 44, 165-169.	21.4	170
23	The Gene Topography of Cancer. Science, 2007, 318, 1079-1080.	12.6	5
24	High frequency of BRAF mutations in nevi. Nature Genetics, 2003, 33, 19-20.	21.4	1,547